Type 2 Diabetes
Stories
-
Eli Lilly posts Phase 3 orforglipron results against dapagliflozin
Eli Lilly posted ACHIEVE-2 results on ClinicalTrials.gov on 2026-10-16. The record reports Week 40 blood-sugar and body-weight measures in 962 adults with type 2 diabetes taking metformin.
-
Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study
The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.
-
Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes
The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.